Last reviewed · How we verify
hydrocodone plus acetaminophen
Hydrocodone is an opioid agonist that binds to mu opioid receptors in the central nervous system to reduce pain perception, while acetaminophen inhibits prostaglandin synthesis to provide additional analgesic and antipyretic effects.
Hydrocodone is an opioid agonist that binds to mu opioid receptors in the central nervous system to reduce pain perception, while acetaminophen inhibits prostaglandin synthesis to provide additional analgesic and antipyretic effects. Used for Moderate to moderately severe pain.
At a glance
| Generic name | hydrocodone plus acetaminophen |
|---|---|
| Sponsor | University of California, Davis |
| Drug class | Opioid analgesic combination |
| Target | Mu opioid receptor (hydrocodone); COX inhibitor (acetaminophen) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Hydrocodone acts as a mu opioid receptor agonist, modulating pain signals in the brain and spinal cord. Acetaminophen works through a separate mechanism, likely involving inhibition of cyclooxygenase enzymes and central nervous system prostaglandin production. The combination provides synergistic pain relief through dual mechanisms.
Approved indications
- Moderate to moderately severe pain
Common side effects
- Drowsiness
- Dizziness
- Lightheadedness
- Nausea
- Constipation
- Respiratory depression
- Hepatotoxicity (acetaminophen-related)
Key clinical trials
- Post-operative Pain Management in Children With Supracondylar Humerus Fractures (PHASE4)
- SCHF Post-Op Study Between Opioid and Non-Opioid Pain Management (PHASE4)
- Connective Tissue Matrix Compared to Steroid Injections for Rotator Cuff Tendinopathy (NA)
- An Artificial Intelligence Driven Approach to Optimize Patient Selection for a Transitional Pain Service (PHASE3)
- Post-Op Pain Control for Prophylactic Intramedullary Nailing. (PHASE3)
- Multimodal Analgesia Effect on Post Surgical Patient (PHASE4)
- Prospective Opioid-Free AIS Fusion (PHASE4)
- Post-Operative Analgesic Selection in Patients Planned for Third Molar Extraction After Undergoing Shared Decision Making Using 2- Versus 3-Option Decision-Aids (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- hydrocodone plus acetaminophen CI brief — competitive landscape report
- hydrocodone plus acetaminophen updates RSS · CI watch RSS
- University of California, Davis portfolio CI